Latest Earnings Results: Q2 '26
Estimated EPS
-$0.18
Reported EPS
-$0.20
Surprise
-8.7%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
OS Therapies reported a net loss of $19.0 million for the six months ended June 30, 2026, with research and development expenses totaling $13.4 million during the same period.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.14 | -- | -- | N/A |
Q2 '26 | -$0.18 | -$0.20 | -8.70% | MISSED |
Q1 '26 | -$0.20 | -$0.27 | -33.66% | MISSED |
Q4 '25 | -$0.25 | -- | -- | N/A |
Q3 '25 | -$0.16 | -$0.21 | -31.25% | MISSED |